Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Frontiers in ImmunologyOpen Access

Liquid biopsy, multi-cancer early detection, and artificial intelligence: new frontiers in cancer screening from a technological and immunological perspective

View Full Paper
Ask AI
Bookmark
Share

Authors

DWDong WuQYQing YuQWQixiang Wu

Discussion

Loading...

Member takes

Overview

Review evaluates liquid biopsy technologies and AI for cancer detection, highlighting predictive value and clinical implications.

Key Points

  • This review aims to assess liquid biopsy technologies and their integration with AI in cancer screening and detection.
  • Critically evaluates major liquid-biopsy analytes and their clinical implications.
  • Discusses MCED as a clinical pathway with emphasis on predictive values and cost-effectiveness.
  • Examines the role of AI in model development and clinical implementation.
  • Identifies various liquid biopsy analytes with clinical potential but highlights many remain investigational.
  • Stresses the importance of predictive values and addressing overdiagnosis in early cancer detection.
  • Notes that while some assays are clinically supported, many emerging models require further validation and oversight.

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/6a362d32db0793dc1a535a42https://doi.org/10.3389/fimmu.2026.1854718
View Full Paper
Ask AI
Bookmark
Share